Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.

Yerram P, Reiss SN, Modelevsky L, Gavrilovic IT, Kaley T.

J Neurooncol. 2019 Oct;145(1):57-63. doi: 10.1007/s11060-019-03266-0. Epub 2019 Aug 20.

PMID:
31432377
2.

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.

Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ.

Neuro Oncol. 2014 Nov;16(11):1523-9. doi: 10.1093/neuonc/nou118. Epub 2014 Jun 23.

3.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
4.

Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.

Rajkumar SV, Buckner JC, Schomberg PJ, Pitot HC 4th, Ingle JN, Cascino TL.

Neurosurgery. 1999 Jan;44(1):67-73.

PMID:
9894965
5.

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.

Hummel TR, Salloum R, Drissi R, Kumar S, Sobo M, Goldman S, Pai A, Leach J, Lane A, Pruitt D, Sutton M, Chow LM, Grimme L, Doughman R, Backus L, Miles L, Stevenson C, Fouladi M, DeWire M.

J Neurooncol. 2016 Mar;127(1):53-61. doi: 10.1007/s11060-015-2008-6. Epub 2015 Dec 1.

PMID:
26626490
6.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
7.

Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.

Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, Nelson JS, Weinstein AS, Curran WJ Jr.

Cancer. 1996 Apr 15;77(8):1535-43.

PMID:
8608540
8.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

9.

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME.

J Clin Oncol. 2000 Oct 15;18(20):3522-8.

PMID:
11032594
10.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
11.

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.

Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA, Dinapoli RP.

Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):297-302.

PMID:
9457812
12.

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

Schold SC Jr, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD, et al.

J Clin Oncol. 1993 Jan;11(1):77-83.

PMID:
8418246
13.

The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.

Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M.

Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43.

PMID:
10348282
14.

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.

Reiss SN, Yerram P, Modelevsky L, Grommes C.

J Immunother Cancer. 2017 Dec 19;5(1):99. doi: 10.1186/s40425-017-0302-x.

15.

Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.

Akiyama Y, Kimura Y, Enatsu R, Mikami T, Wanibuchi M, Mikuni N.

World Neurosurg. 2018 May;113:e508-e514. doi: 10.1016/j.wneu.2018.02.070. Epub 2018 Feb 21.

PMID:
29476996
16.

Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR; North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials.

J Clin Oncol. 2006 Aug 20;24(24):3871-9.

PMID:
16921039
17.

Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.

Hochberg F, Prados M, Russell C, Weissman D, Evans R, Cook P, Burton G, Eisenberg PD, Valenzuela R, Verkh L.

J Neurooncol. 1997 Mar;32(1):45-55.

PMID:
9049862
18.

Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?

Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, Champ CE, Zhang I, Bar-Ad V, Kim L, Glass J, Evans JJ, Andrews DW, Werner-Wasik M, Shi W.

J Neurooncol. 2018 Dec;140(3):623-628. doi: 10.1007/s11060-018-2989-z. Epub 2018 Sep 4.

PMID:
30182159
19.

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.

Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.

Br J Neurosurg. 2013 Dec;27(6):772-8. doi: 10.3109/02688697.2013.791664. Epub 2013 May 11.

PMID:
23662801
20.

Supplemental Content

Support Center